Farrelly Joseph W sold $2.2M of CPAY

Farrelly Joseph W sold 5,300 shares of CORPAY, INC. (CPAY) at an average of $410.00 ($405.09–$415.03, $2.17M total) across 3 trades over 2026-08-12 to 2026-08-13.

Original reporting
SEC EDGAR · Farrelly Joseph W
Published Aug 14, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CPAY
Neutral
medium confidence
Mentioned
$CPAY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CPAYNeutralLow
01

Why it matters

A director’s open-market sale totaling $2.17M is a new, concrete datapoint for insider-trading sentiment, but it does not include any new corporate event (earnings, guidance, deal, or regulatory action).

02

Market read

Traders may briefly reassess sentiment around CPAY due to insider selling, but the disclosure alone is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The filing does not state a 10b5-1 plan, but it also provides no reason for the sale, so interpreting it as bearish may be overstated.

Relevance 6/10Novelty 5/10Timing: filed 2026-08-14 after-hours (SEC Form 4 disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Corpay, Inc. (CPAY).

Company-level read

Ticker impact

$CPAYNeutralMedium confidence
Context

Director Farrelly Joseph W sold about 5,300 shares of Corpay in open-market trades totaling $2.17M, per a new Form 4 filed today.

Expected impact

Likely limited, short-lived sentiment impact; watch for follow-on insider activity or concurrent company news.

Evidence & confidence

This is a routine Form 4 open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

No sector-level implications disclosed; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for diversification or tax, and the article provides no evidence of negative company fundamentals.

Key entities

  • CORPAY, INC.

    Subject of the Form 4 insider sale disclosure.

  • Farrelly Joseph W

    Director who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CPAYMed

What Corpay (CPAY) Said on Its Q3 Earnings Call

Corpay (CPAY) reported Q3 gross margin at 30.4%, up from Q2 but down annually. Cash position was CAD 50.6M. Acquired AISPECO for airborne sensors. Expects revenue synergies sooner. Plans to scale manufacturing and expand commercial/defense businesses. Corpay provides corporate payment solutions.

$CPAYMedAI 8/10

Corpay 3Q 2026: Revenue $1.38B, EPS $5.66 — 10-Q Summary

Corpay reported 3Q 2026 revenue of $1.38B, up 17.9% YoY, and net income of $378.42M, up 36.2% YoY. Growth was driven by organic spend and transaction volumes, new sales, and acquisitions. Higher operating expenses and other costs partly offset gains. Management expects liquidity to meet needs for the next 12 months.

$CPAYHighAI 8/10

Corpay (CPAY) Q3 2026 Earnings Call Transcript

Corpay (CPAY) raised Q4 2026 revenue guidance to $1.37B and cash EPS to $7.65, up 27%. Full-year 2026 revenue is expected to rise 18%, with cash EPS up over 30%. For 2027, Corpay anticipates 9-11% organic revenue growth. The company has divested noncore businesses, using proceeds for share buybacks, and plans to allocate $2B in free cash flow to acquisitions or buybacks. Corporate Payments segment growth is expected to remain in the high teens.

$CPAYMed

Corpay Q3 Earnings Call Highlights

Corpay (NYSE:CPAY) expects 9-11% organic revenue growth in 2027, with $2B in free cash flow for acquisitions or share repurchases. The company divested noncore businesses in 2026, using proceeds for buybacks. Alpha and Avid are expected to contribute over $1.40 in combined cash EPS accretion in 2026. Corpay aims to compound adjusted EPS by over 20% annually through 2029.